Original Article

Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases

Dora E. Corzo-León[1,2], Luis D. Chora-Hernández[1,3], Ana P. Rodríguez-Zulueta[1] and Thomas J. Walsh[4,*]

[1]Department of Epidemiology and Infectious Diseases, Hospital General Dr. Manuel Gea González, Mexico City, Mexico, [2]Medical Mycology and Fungal immunology / Wellcome Trust Strategic Award Program. Aberdeen Fungal Group, University of Aberdeen, Aberdeen, UK, [3]Department of Infectious Diseases. Hospital General No. 1 Instituto Mexicano del Seguro Social. Morelia Michoacan and [4]Transplantation-Oncology Infectious Diseases Program and Infectious Diseases Translational Research Laboratory, Departments of Medicine, Pediatrics, and Microbiology & Immunology, Weill Cornell Medicine of Cornell University, New York, NY, USA

*To whom correspondence should be addressed. Dr. Thomas J. Walsh, 1300 York Ave., Rm A-421, New York, NY 10065, Tel: +212-746-6320 (main office); Fax: +212-746-8675; E-mail: thw2003@med.cornell.edu

Abstract

Mucormycosis is an emerging infectious disease with high rates of associated mortality and morbidity. Little is known about the characteristics of mucormycosis or entomophthoromycosis occurring in Mexico. A search strategy was performed of literature published in journals found in available databases and theses published online at Universidad Nacional Autónoma de México (UNAM) library website reporting clinical cases or clinical case series of mucormycosis and entomophthoromycosis occurring in Mexico between 1982 and 2016. Among the 418 cases identified, 72% were diabetic patients, and sinusitis accounted for 75% of the reported cases. Diabetes mellitus was not a risk factor for entomophthoromycosis. Mortality rate was 51% (125/244). *Rhizopus* species were the most frequent isolates (59%, 148/250). Amphotericin B deoxycholate was used in 89% of cases (204/227), while surgery and antifungal management as combined treatment was used in 90% (172/191). In diabetic individuals, this combined treatment approach was associated with a higher probability of survival (95% vs 66%, OR = 0.1, 95% CI, 0.02–0.43' $P = .002$). The most common complications were associated with nephrotoxicity and prolonged hospitalization due to IV antifungal therapy. An algorithm is proposed to establish an early diagnosis of rhino-orbital cerebral (ROC) mucormycosis based on standardized identification of warning signs and symptoms and performing an early direct microbiological exam and histopathological identification through a multidisciplinary medical and surgical team. In summary, diabetes mellitus was the most common risk

factor for mucormycosis in Mexico; combined antifungal therapy and surgery in ROC mucormycosis significantly improved survival.

Key words: Mucormycosis, Mexico, Epidemiology, Treatment, Diagnostic Algorithm.

Introduction

Mucormycosis is an emerging infectious disease, which affects mainly immunocompromised patients. Mucormycosis is associated with high mortality (>50%) and disability rates.[1–3] Early diagnosis and initiation of therapy significantly improves survival and decreases morbidity.[4–8] Advances in clinical laboratory methods also may provide an earlier diagnosis.[4] Recognition of risk factors is a key element for early clinical diagnosis of mucormycosis.

Risk factors for mucormycosis may vary considerably by country. Studies from France, United States, and Greece indicate a shift from diabetes mellitus to hematological malignancies as a leading risk factor.[3,6,9,10] French investigators also describe trauma as an important emerging risk factor for mucormycosis in their country.[11] By comparison, reports from Iran and India describe diabetes mellitus as the predominant risk factor for mucormycosis.[12–14]

Little is known about the risk factors for mucormycosis in Latin American countries. Given the estimated population of Latin American countries of more than 500 million people (https://www.census.gov/en.html), including approximately 120 million in Mexico (http://www.inegi.org.mx), understanding the risk factors for this uncommon but frequently lethal mycosis is important. We therefore conducted a systematic review of the epidemiology, clinical manifestations, and outcome of cases of mucormycosis in Mexico. To our knowledge there are no prior comprehensive reviews about mucormycosis in the country of Mexico.

Methods

Objectives

The aims of this study are (1) to characterize the epidemiology and clinical manifestations of mucormycosis in Mexico based on a comprehensive literature review of all reported cases and (2) to propose a clinical diagnostic algorithm for mucormycosis in patients with diabetes based on the observations made from literature reviewed in this study.

Literature search and identification of cases published in journals.

A search strategy in the English and Spanish literature was performed using the databases and search engine tools LILACS, Scielo, EMBASE, MEDLINE, Google scholar, and Medigraphic. Terms used for search were "phycomycosis," "zygomycosis," "mucormycosis, "Zygomycetes," "*Mucor,*" "*Phycomycosis,*" "*Rhizopus,*" "*Rhizomucor,*" "Mucorales," "*Apophysomyces,*" "*Cunninghamella,*" "*Absidia,*" "*Lichtheimia*" (and also with the corresponding Spanish term) and the filter term: "Mexico," "Mexican," "Latin America"; see Figure 1.

Literature search and identification of cases from theses and meetings.

We also searched on the central database of the National University of Mexico (UNAM) library (http://biblioteca central.unam.mx), and medical literature reported in international (Workshop of the ECMM/ISHAM Working group on Zygomycetes Utrecht, The Netherlands 2013) and national medical annual meetings (Mexican Society of Infectious Diseases Annual Meeting 2013) with the same search criteria. We included only literature reporting cases of mucormycosis from Mexican hospitals.

Inclusion of cases of mucormycosis.

All cases of mucormycosis in Mexico published between 1970 and March 2016 who fulfilled EORTC/MSG consensus group criteria for proven and probable invasive fungal infection[5] were included in this report. These criteria were applied in a manner similar to that of the different populations at risk for mucormycosis as recently described.[6,11] Exclusion criteria included infections not occurring in Mexico, information not available online, and reports that were redundantly duplicated in different databases (Fig. 1). Clinical information including comorbidities, age, sex, methods for laboratory diagnosis, isolates, clinical presentation and site of infection, complications, year of publication, management received, and outcome (mortality, time until treatment, resolution) were registered in the database.

Statistical analysis and software

Excel (Microsoft, Redmond, Washington, US) was used to build the database. Data are presented as proportions and percentages. When the performance of diagnostic tests was analyzed, the performance was reported also by type of center doing the diagnosis. Types of center were categorized as specialized and nonspecialized. A specialized center was defined as having a mycology laboratory only focused on

Figure 1. Results of the search strategy. This figure summarizes the literature excluded and included for this study. The search strategy was done in English and Spanish literature using several online resources.

the diagnosis and identification of fungi and which is known also to be providing technical training to other parties. Differences in proportion for mortality were analyzed by χ^2 (InStat, GraphPad Software, San Diego, CA).

Logistic regression analysis for mortality risk factors was performed. For this analysis, only individuals with diabetes were included based on complete information about outcome, risk factors for mortality, and treatment. Only variables with a P value $\leq$ .1 in univariate analysis were included in the logistic regression model. Sex and age were included in the model as control variables although their P value was >.1. Odds ratio and 95% confidence intervals were estimated. The regression was performed used SPSS Inc 21 software (IBM corporation, New York, US).

Clinical diagnostic algorithm

This *clinical diagnostic algorithm* was developed based on findings in this study to include the most frequent type of infection, population affected, complications, diagnostic tests performed, disciplines involved in diagnosis and management. This algorithm also was aligned with international guidelines for management of mucormycosis,[15] especially as Mexican guidelines for treatment of mucormycosis are not available.

Results

Documents reviewed

A total of 221 documents were found; these include 28 theses from the Universidad Nacional Autónoma de México (UNAM) and 193 published papers from which 13 theses and 39 papers were included following the inclusion criteria (Fig. 1). In addition, cases reported in one International and one Mexican annual meeting were included. A total of 414 cases of mucormycosis and four of entomophthoromycosis were found among these documents. The first report available was published in 1990 and included cases occurring from 1982 to 2015.

Demographic characteristics

The main characteristics are summarized in Table 1. Slightly more cases occurred in males (54%). The median age was 42 years (0–80 years old). Diabetes mellitus was the more frequent underlying condition (72%). This preponderance of cases was maintained since 1982 until 2016; however, the number of cases of mucormycosis reported among individuals with neoplastic diseases increased during the last decade (Fig. 2).

Table 1. Demographic and clinical characteristics: differences between populations with diabetes and malignancy.

Characteristic	Diabetes N = 302/418 (72%)	Malignancy* [77/418 (18% Hematological 72/77 (93%)]	Total population** N = 418 (%)
Age, years (median, IIR)	50 (38–60)	26 (18–43)	42 (0–80)
Sex (Male)	96/187 (51)	11/27 (41)	225 (54)
Mortality rate	101/192 (53)	11/25 (44)	127/246 (52)
N = 246 (%)ᵃ		11/23 (48)	
Type of infectionᵇ	N = 181 (%)	N = 31 (%)	N = 418 (%)
Sinus (overall)	159 (88)	11 (35)	315 (75)
Palatine infection	39/159 (24)	2/11 (18)	45/315 (14)
Sinocerebral/cerebral	85/159 (53)	3/11 (27)	210/315 (66)
Pulmonary	8 (4)	11 (35)	26 (6)
Cutaneous	9 (5)	2 (6)	28 (6.5)
Disseminated+	2 (1)	4 (13)	23 (5.5)
Unspecified***	1 (0.5)	0	19 (4.5)
Abdominal++	1 (0.5)	3 (10)	5 (1)
Cerebral &	1 (0.5)	0	2 (0.5)

IIR, Interquartile interval range.

ᵃMortality rate estimated with the available information of 246 individuals.

ᵇType of infection was estimated depending on the number of individuals with available information: 181 with diabetes mellitus and 31 with malignancy. Although an overall estimation was possible for some variables among the 418 cases, in some reports only the site of infection was reported without mention of the underlying disease.

* Five individuals with malignancy had diabetes mellitus as comorbidity

** Includes cases without underlying condition or without diabetes and without malignancy (N = 39, 9.3%). This group had mortality rate in 52% (15/29). Ten individuals with no underlying condition (19/39, 49%) did not have information available and eight were reported as previously healthy. Prior trauma was present in eight of 39 (20%), of these five individuals had no other associated condition. Five individuals had autoimmune disease (5/39, 13%), three with HIV (human immunodeficiency virus) infection (3/39, 8%), other prior conditions were drug toxicity (2/39, 5%), post-surgery (2/39, 5%). Drug toxicities consisted in agranulocytosis or neutropenia due to drugs. Numbers reported in populations with diabetes and malignancy vary due to the availability of the information.

*** Unspecified: refers to information of the site/type of infection was unavailable

+2 or more sites affected.

++Only abdominal infection. These were gastric, renal, hepatic, splenic, and intestinal presentation.

&Only due to trauma and postsurgical process, no sinus infection.

Information about the metabolic status of diabetes mellitus was available for 176 cases of which 74 (42%) presented ketoacidosis state at the time of the diagnosis of mucormycosis. Among the 77 patients with malignancies, information about the type of malignancy was available for 68 individuals. Among these 68 patients, 37 (54%) were reported to have acute leukemia, followed by 14 (20%) cases with acute lymphoblastic leukemia, 6 (9%) with acute


Cases of mucormycosis and entomophthoromycosis reported since 1982

Figure 2. Cases of mucormycosis and entomophthoromycosis in Mexico reported in the literature. Bar chart showing the raw number of cases reported over the time and by medical condition.

myeloid leukemia, 5 (7%) with solid tumor, and 4 (6%) with non-Hodgkin's lymphoma.

Clinical presentation and mortality rate

Sinus infection was the predominant type of infection in 75%, followed by pulmonary disease in 6% (Table 1). As information about clinical presentation by host population was not given by all the reports, the analysis of clinical presentation by host population was performed only with the information available. For the diabetes population, information corresponding to clinical presentation was available for 181 patients, among whom 159 (88%) cases had sinus infections. This contrasts with the population with neoplastic conditions (n = 31 available), where pulmonary and sinus presentations were similar (Table 1 and Fig. 3).

The median time between the beginning of symptoms of mucormycosis and initiation of antifungal therapy was 15 days (IQR 7–30 days). No differences in mortality rates were noted between the delay of management at day 7 or 14. Among the 188 cases, 97 (52%) had documented progressive mucormycosis despite antifungal therapy.

Complications

The main complications of mucormycosis reported in the study patient population are summarized in Tables 2 and 3. These complications are (1) those caused by mucormycosis itself, including but not limited to cavernous sinus thrombosis, disseminated infection, periorbital destruction, palatine ulcers, osteomyelitis, and death (2) those secondary to antifungal management, including but not limited to nephrotoxicity, hypokalemia, prolonged hospitalization (15–30 days due to IV antifungal management and surgeries), bacterial superinfection and (3) those resulting in functional impairment or anatomical deformities, such as orbital exenteration, requiring reconstructive surgeries, prosthesis, and chronic rehabilitation after debulking surgery.

Mortality

Overall mortality in this population with mucormycosis was 52% (127 of 246 cases). No differences were found between subpopulations (diabetes [101/192, 53%], malignancy [11/25, 44%] and others [15/29, 52%], P = .7). Among diabetic patients with mucormycosis, those presenting with ketoacidosis had a higher rate of mortality (64% [36/56] vs 43% [33/75], P = .02) than those nonketotic patients with diabetes mellitus by univariate analysis. However, ketoacidosis was not an independent risk factor for mortality by logistic regression analysis (Table 4). Post


Figure 3. Clinical presentations of mucormycosis and entomophthoromycosis in Mexico. Pie charts showing the clinical presentations by underlying condition using proportions.

mortem diagnosis was established in 16 cases, 7 of them had disseminated mucormycosis.

Laboratory Diagnosis

The laboratory diagnostic procedures by which the mucormycosis was identified were histopathology, direct

Table 2. Published case reports in Mexico.

Author	Year and place of publication reported	Summary of study	Complication
Gutierrez-Delgado EM[44]	2016 Monterrey NL	Describes characteristic of chronic mucormycosis	Tubulointerstitial nephritis associated with amphotericin B treatment
Alvarado-Lezama JA[45]	2015 Puebla	Reports emphysematous gastritis due to mucormycosis	Death due to septic shock
Hernandez Mendez H et al.[46]	2015 Mexico City	Describes dental procedures done one year after mucormycosis.	After mucormycosis, the main complication was breathing by mouth only
Rodriguez-Gutierrez G et al.[47]	2015 Mexico City	*Syncephalastrum racemosum* as causative agent of pulmonary mucormycosis in a non-Hodgkin T cell lymphoma diagnosed by PCR.	Not mentioned
Bonifaz A et al.[48]	2014 Mexico City	*Apophysomyces mexicanus* reported as new species causing cutaneous mucormycosis. Cutaneous mucormycosis after neck lacerations and T12 vertebral fracture after car accident.	Death due to mucormycosis
Valdez-Geraldo CM[49]	2014 La Paz, Baja California Sur	ROC mucormycosis and diabetic ketoacidosis diagnosed for first time in an 11 year-old girl	3 months of antifungal management and protracted hospital length-stay
Plowes et al.[30]	2014 Mexico City	Use of sinonasal endoscopy as key surgical approach for ROC	Thrombosis of cavernous sinus
Bonifaz A et al.[21]	2014 Mexico City	Children with diabetes also are in risk of ROC mucormycosis, 15/22 (68%) cases in this report had it.	High rate of mortality (>70%) in pediatric population
Camara-Lemarrow et al.[22]	2014 Monterrey, NL.	Fourteen cases. Higher survival in younger individuals	6 of 14 individuals with hypokalemia and kidney injury.
Zamora-de la Cruz D[50]	2013 Guadalajara, Jalisco	Mucormycosis in an individual with aplastic anaemia managed with combined antifungal and surgery	Ocular prosthesis could not be available before 6 months
Ramirez-Dovala et al.[51]	2012 Mexico City	Identification intraoperative with KOH. PCR for final identification.	Death due to septic shock
Gonzalez-Ramos LA[52]	2012 Hermosillo, Sonora	Reports endocarditis due to mucormycosis in a 3 year-old boy	Death due to disseminated infection
Telich-Tarriba et al.[53]	2012 Mexico City	Early diagnosis with intraoperative biopsy. Recovery after 2 weeks of combined management.	Necrotizing fasciitis.
Garcia-Romero MT et al.[54]	2011 Mexico City	Role of nasal endoscopy in diagnosis and follow up of ROC mucormycosis	Delays in diagnosis and treatment.
Ayala-Gaytan et al.[55]	2010 Monterrey, NL.	After surgery and at least 15 days of IV antifungal management, full recovery	Not mentioned
Arce-Salinas CA.[56]	2010 Mexico City	Red flags/ warning signs leading the diagnosis: ocular pain, and diplopia in SLE on high doses of corticosteroids.	nerve paralysis and palatal ulcer

Table 2. *Continued*

Author	Year and place of publication reported	Summary of study	Complication
Cortez-Hernandez et al.	2010 Culiacan, Sinaloa	Pulmonary mucormycosis is a 5 year-old child. Trans-surgical diagnosis. Survival after 28 days of IV antifungal therapy.	Not mentioned
Ramirez et al.[57]	2009 Mexico City	Mucormycosis after neutropenia associated with drugs (metimazol). Recovery after surgery, 1 month of antifungal therapy and reconstructive surgery***	Long hospital length-stay
Salinas-Lara et al.[58]	2008 Mexico City	Extremely rare pituitary apoplexy due to mucormycosis	Pituitary apoplexy
Bonifaz A. et al.[59]	2008 Mexico City	Symptoms began 9 days before diagnosis and palatine ulcer 5 days before. Complete response 4/21 (19%). Direct exam using KOH identified 21/21 cases of ROC. Antifungal therapy IV treatment was used for 12–25 days.	Not mentioned
Ameen et al.[23]	2007 Mexico City	Mucormycosis after venepuncture. Multidisciplinary approach and management	Not mentioned
Robledo-Ogazon et al.[60]	2007 Mexico City	Consider mucormycosis in deep infections after trauma	Dead due to septic shock
Torres-Chavez T et al.[61]	2007 Mexico City	Mucormycosis after dental extraction	Dead due to cardiovascular failure
Papadakis-Solis M et al.[62]	2007 Mexico City	Necrotic nasal tissue, and palatine ulcer as red flags/ warning signs. Using 3-phase bone scan to determine extension of surgical resection.	Not mentioned
Zurita R.	2006 Monterrey, NL	Describes diabetic foot infection due to mucormycosis in a renal transplant recipient	Nephrotoxicity and amputation
Carrillo-Esper et al.[63]	2006 Mexico City	Renal mucormycosis in a lymphoblastic leukaemia patient. Combined management with caspofungin and amphotericin B deoxycholate	Not mentioned
Alvarez-Leyva MA[64]	2005 Oaxaca	Describes a case of ROC in diabetes	Difficult metabolic control
Martin-Mendez HM et al.[65]	2005 Mexico City	Orbital apex syndrome as a red flag/ warning sign for diagnosis	Sinus thrombosis and stroke as causes of death.
Carrada-Bravo T.[66]	2004 Irapuato, Gto.	Rhinosinusitis Mucormycosis in a HIV person. Three months of antifungal therapy and surgery.	Long hospital length of stay
Castillo-García A[67]	2004 Mexico City	Reports 8 of 13 cases of ROC due to *Mucor* sp in diabetic patients	8 of 13 deceased.
Lara-Torres et al.[68]	2004 Mexico City	Mucormycosis necrotizing gastro enterocolitis. Highlights the gastrointestinal infection seen frequently among children	Deceased

Table 2. *Continued*

Author	Year and place of publication reported	Summary of study	Complication
Fujarte Victorio AS et al.[69]	2003 Mexico City	Mucormycosis co-diagnosed with small cell lung carcinoma. Management with 30 days of IV Amphotericin B deoxycholate.	Not mentioned
Hernandez-Magaña R et al.[70]	2001 Mexico City	Nosocomial acquisition of cutaneous mucormycosis in a 6-month old child	Loss of soft tissue of malar region nasal destruction
Barron-Soto et al.[71]	2001 Mexico City	14/24 (42%) individuals required orbital exenteration. Reports high mortality rate (54%) among 24 individuals with diabetes.	High mortality rate
Romero-Zamora JL et al.[72]	2000 Mexico City	12 diabetic individuals received at least 20 days of IV antifungal therapy. Red flags/ warning signs: palatine ulcer, cranial nerve paralysis. Mortality of 25%.	Super bacterial infection, and ketoacidosis as cause of death.
Salazar-Flores M.[73]	2000 Mexico City	Disseminated mucormycosis after pneumonia. Diagnosis premortem was not possible due to lack of cultures during their hospital stay.	Death due to septic shock.
Bross-Soriano D et al.[74]	1998 Mexico City	Describes four acute cases of mucormycosis and new diagnosis of diabetes mellitus	Death due to septic shock.
Rangel-Guerra RA et al.[75]	1996 Monterrey, NL	Eleven out of 22 patients with ROC and diabetes required maxillectomy and orbital exenteration (50%). All five disseminated mucormycosis cases were diagnosed post-mortem	Not mentioned
Escobar et al.[76]	1990 Mexico City	Brain abscess in SLE by mucormycosis could have a distant origin, such as skin venepuncture.	Deceased

ROC, Rhino-orbito-cerebral mucormycosis. SLE, Systemic lupus erythematous.

cytology/smear, and cultures. Information about histopathology was available for 223 cases, and among these, 197 (88%) were positive. Among 234 cases reporting the results of direct cytology/smear, 231 cases were positive (98%). Among these same 234 cases, the culture positivity was 76% ($n = 179$). The overall performance rate for culture was 71% (262 positive cultures among 369 cases available to evaluate). However, the performance rate of cultures reported by specialized mycology centers (142/158 [90%]) was higher than those for cases reported by nonspecialized centers (120/211 [57%]) ($P < .0001$), Table 5.

Mycological identification

Among 250 reported isolates, the most frequent organisms recovered were *Rhizopus* spp. (59%) followed by *Mucor* spp. (28%), and *Rhizomucor* spp. (4%) (Table 6). While culture remains the most common method for identification, yield of cultures continues to be low in mucormycosis and mold infections in general. In Mexico, more recent reports, since 2012, described the use of molecular methods including newly described species such as *Apophysomyces mexicanus* (Tables 2 and 3).

Management

Information about management was available for 244 patients, and the information about the type of antifungal agent administered for 227 individuals. Amphotericin B deoxycholate (AmBD) was used in 89% of cases, and 23 cases (11%) received AmBD plus another antifungal agent. Antifungal therapy without surgery was documented in 29 (13%) of 227 individuals (Table 7). Two hundred and nine

Table 3. Doctoral theses written and published online at Universidad Nacional Autónoma de México (UNAM) library website.

Author of thesis	Year	Number of cases	Summary of the study
Pedroza-Teran LG[77]	2016	11	Reports cases between 2011 and 2015. Evaluate in detail main complications associated with the management of mucormycosis such as nosocomial infections and acute renal injury.
Alamilla-Azpeitia RS[78]	2015	1	Reports a nurse healthcare program after mucormycosis.
Tepox-Padron A[79]	2014	36	Cases since 1987 to 2013. Prior steroid treatment was found in 47%. Bivariate analysis did not find mortality risk factors.
Rodriguez-Gutierrez G[80]	2013	14	Cases since 1994–2013. PCR and sequencing are useful diagnostic tools.
Chavez-Martinez S.	2011	4	Describes maxillofacial rehabilitation after treatment and reconstructive surgeries
Avila-Cardoso C[81]	2010	19	Cases reported 2004–2009. Describes the main affected structures in ROC mucormycosis.
Gomez-Castelán A[82]	2007	1	Case diagnosed in 2001. Details rehabilitation with ocular prosthesis 5 years after mucormycosis.
García-Luis D[83]	2005	1	Describes evolution of mucormycosis in a diabetic patient.
Rodriguez.Osorio C[84]	2004	15	Reports cases between 1987 and 2004. Describes side effects related with Amphotericin B deoxycholate and also describes a mean length of hospital stay of 41 days.
Acuña-Ayala H[85]	2002	24	Reports cases from 1982 to 2000. Only 8/24 cases are included due to the rest were published elsewhere.
Luna Olguín L[86]	2000	2	Describes two cases diagnosed in 1999
Melendez Rivera L[87]	1999	31	Reports cases diagnosed between 1986 and 1998. Post mortem diagnosis made in four cases. Only nine with diabetic ketoacidosis.
Martinez, Martinez M[88]	1996	1	Reports a case with diabetic ketoacidosis

ROC, Rhino-orbito-cerebral mucormycosis.

individuals with the complete information about treatment and outcome were selected and analyzed. Surgery and antifungal management were used in 77% of these (162/209), and management with only an antifungal agent was used in 14% (29/209). Those who received combined management with surgery and one antifungal agent had lower mortality rate when compared to those who received antifungal therapy only (76/162, 47% vs 22/29, 76%, respectively, $P = .004$), (Table 7).

Logistic regression analysis

In logistic regression analysis, which only included diabetic individuals with complete information to be analyzed (N = 91), we also found higher survival for those receiving surgery and antifungal agent as management strategy when compared with antifungal use only (70% [53/76] vs 20% [3/15]). Combined treatment approach was associated with a higher probability of survival (95% vs 66%, OR = 0.1, CI 95% 0.02–0.43, $P = .002$) independently of sex, age, and ketoacidosis status (Table 4).

Discussion

This study underscores that the preponderance of mucormycosis in Mexico occurs in patients with diabetic mellitus. This finding is important as most reports in more economically developed countries are reporting patients with hematological malignancies, and transplant recipients as the predominant and increasing population in relation to a decreasing proportion of cases with diabetes mellitus.[6,8,16] Unlike previous studies, in which higher mortality rate in patients with hematological malignancies[17] in comparison to those with diabetes mellitus has been reported, our study, found a similar rate of mortality between these two groups. However, when we compare mortality rate of diabetic

Table 4. Risk factors associated with death in 91 diabetic individuals assessed by multivariate logistic regression analysis.

Characteristic	Vital status		Univariate	Multivariate analysis		
	Survived N = 56(%)	Dead N = 35(%)	P value	OR	95% CI	P value
Sex (Female)	26 (41)	24 (50)	.36	1.57	0.60–4.24	.36
Age	48 ± 16	47 ± 15	.53	0.98	0.95–1.02	.43
Ketoacidosis	20 (33)	18 (38)	.68	1.91	0.67–5.41	.22
Surgery and antifungal therapy*	53 (95)	23 (66)	.001	0.10	0.02–0.43	.002
Cutaneous infection	5 (9)	3 (9)	.71			
Pulmonary infection	5 (9)	3 (9)	.71			
ROC infection	46 (83)	29 (83)	.92			
Abdominal	0	3 (8)	.99			
Disseminated	0	1 (3)	.99			

CI, confidence interval. OR, odds ratio.

*Surgery and antifungal therapy vs antifungal therapy only.

X^2 value 17.02, $P = .002$.

Table 5. Performance of diagnostic testing.[a]

Diagnostic tool used	Reports from nonspecialized centers	Reports from specialized center	Overall
Positive direct smear/cytology	73/ 76 (95%)	158/158 (100%)	231/234 (98%)
Positive culture	120/211 (57%)	142/158 (90%)	262/369 (71%)

[a]158 (41%) of 369 cases were reported by a specialized center of diagnostic mycology, while 211 cases were reported by nonspecialized centers.

Table 6. Clinical isolates reported from 250 patients.

Organism isolated	Total population n = 250 (%)
Rhizopus species	148 (59)
Rhizopus oryzae/R. arrhizus	108/148 (73)
Rhizopus sp.	34/148 (23)
Rhizopus rhizopodiformis	2/148 (1.3)
Rhizopus microsporus	2/148 (1.3)
Rhizopus azygosporus	1/148 (0.6)
Rhizopus pusillus	1/148 (0.6)
Mucor species	71 (28)
Mucor sp.	66/71 (93)
Mucor circinelloides	5/71 (7)
Rhizomucor sp.	10 (4)
Lichtheimia corymbifera	8 (3)
Cunninghamella sp.	4 (1.5)
Syncephalastrum racemosum	3 (1)
Basidiobolus sp.	3 (1)
Conidiobolus sp.	1 (0.5)
Apophysomyces mexicanus	1 (0.5)
Absidia sp.	1 (0.5)

population in our report and other previous reports,[17] the rate of mortality was higher in our population. This study further demonstrated that among diabetic patients with mucormycosis, those presenting with ketoacidosis had a higher rate of mortality by univariate analysis. However, ketoacidosis was not an independent risk factor for mortality by logistic regression analysis. Treatment with both antifungal therapy and surgery improved the probability of success.

These findings are similar to prior reports of ROC mucormycosis,[18,19] especially in the diabetic population,[15,20] and those with localized disease.[16] One should note, however, that since patients with disseminated mucormycosis, which carries a poor prognosis, would not usually be candidates for surgery, the benefits of combined surgery and antifungal therapy pertain to patients with localized disease.

As a quality control for verification of the underlying diseases and clinical manifestations of mucormycosis in this cases series, we reviewed the distribution of these variables in several reports from large medical centers in Mexico. A review of 22 cases of mucormycosis in children from a single center in Mexico found that the rhinocerebral form was the main clinical presentation (77%), followed by primary cutaneous and pulmonary patterns.[21] Consistent with the overall findings in the study reported herein, diabetes mellitus was present 68% of these patients and hematologic diseases in 28%. Another study reported the clinical features and outcome of mucormycosis among 14 cases from a tertiary-care teaching hospital in northern Mexico.[22] Compatible with the data of our report, 10 patients had diabetes mellitus, and 6 had a hematological malignancy (acute leukemia) as underlying diseases. Finally, Ameen et al. reported five cases of mucormycosis diagnosed at a tertiary referral center for medical mycology (Dr Manuel Gea Gonzalez General Hospital in Mexico City).[23] ROC mucormycosis in that study was diagnosed in four of five cases; four of these patients had diabetic ketoacidosis.

Table 7. Combined treatment analysis.

Treatment	Population N = 209 (%)	Mortality rate (%)
Antifungal therapy only*	29/209 (14)	22/29 (76)†
Surgery only	3/209 (1)	2/3 (66)
Both surgery and antifungal therapy*	162/209 (77)	76/162 (47)†
Neither**	15/209 (7)	15/15 (100)

*Amphotericin B deoxycholate was used in 204/227 (89%); amphotericin B deoxycholate plus another antifungal agent was used in 23/204 (11%). Other antifungal agent included itraconazole (n = 4); caspofungin (n = 4); fluconazole (n = 5); flucytosine (n = 4); voriconazole (n = 3); posaconazole (n = 3).

**Most cases were identified post-mortem (11/15)

†$P = .004$.

It is well known that mucormycosis is more frequent among individuals with uncontrolled diabetes and hyperglycemic states.[24,25] Hence, glycemic control is a key factor in the management of mucormycosis and also in its prevention;[8,15,26] however, worldwide less than 40% of the diabetic population achieve good glycemic control.[27] Especially, the Latin American population with diabetes has lower proportion of glycemic control when compared with non–Latin American countries.[28,29] In Mexico, specifically, less than 25% of patients with diabetes are in good glycemic control (http://ensanut.insp.mx).

This study demonstrates that ROC mucormycosis in diabetic patients is a life-threatening infection with high mortality. As our own clinical experience suggests that diabetic ROC mucormycosis may be under diagnosed, we propose a clinical diagnostic algorithm to improve recognition at the bedside. We therefore developed a clinical diagnostic algorithm based upon data derived from this study and from our previously reported work.[30] The clinical diagnostic algorithm also was harmonized with international guidelines[15,31] and recommendations of the European Confederation for Clinical Mycology (ECMM) Working group on Zygomycosis.[7] The algorithm is intended to provide guidance for early diagnostic assessment and timely administration of antifungal therapy for patients at risk for ROC mucormycosis, irrespective of country or origin.

Based upon the data reported herein, the algorithm focuses on clinical diagnosis of ROC mucormycosis complicating diabetes mellitus. This approach is especially important for the Mexican population, which has a high prevalence of diabetes.[32] As our study observed that ROC mucormycosis commonly presents as sinusitis with cranial nerve deficits, orbital apex syndrome, and palatine ulcers, these are considered "red flags/warning signs" in this algorithm. In this algorithm, we recommend to look for these red flags/warning signs as a second step after the identification of individuals with diabetes and sinusitis and if the warning signs are identified, we recommend to trigger the approach with blood and image test (Fig. 4).

The algorithm also advocates using diagnostic imaging to serve as a guide for both initial diagnosis, as well as a tool to delimit the infected zone and planning the boundaries of surgery. The algorithm reflects the multidisciplinary medical and surgical approach needed for successful management of mucormycosis. The algorithm advocates using three main tools for laboratory diagnosis of diabetic ROC mucormycosis: [1] perioperative direct cytology/smear, [2] culture and [3] histopathology.

The performance of laboratory diagnostic tools seemed to be better in mycology specialized centers in this study. Among the explanations are the use of special media, optimized growth conditions, identification of Mucorales as a pathogen rather than as contaminant, as well as recognition of its colonial morphology among mixed cultures. The differences also reflect the importance of enhanced microbiology skills and continuous training in medical mycology.

Rhizopus species were the most frequent isolated organism in this study, as has been reported in the United States, India, and Europe.[1,2,13] However, in India,[13] the second most frequent species was *Apophysomyces* spp. instead of *Mucor* spp. as was the case in this study. Notably, the use of molecular diagnostic technology has been increasing as a useful tool for early identification of species causing mucormycosis in Mexico. This strategy is especially helpful to accelerate also the time for genus and species identification. Recovery of DNA may also be a tool for molecular epidemiological studies of mucormycosis.[33–35]

Mucormycosis is not only a high mortality infection but also one that causes anatomical deformities and functional impairments directly from the infection or indirectly from surgical interventions. Therefore, enhancement of clinical skills and implementation of the proposed algorithm (Fig. 4) to establish an earlier diagnosis and multidisciplinary management is essential to reduce mortality and complicating deformities of ROC mucormycosis.

The clinical diagnostic algorithm focuses on the more frequent clinical scenario found in this study, ROC mucormycosis in diabetic patients. The algorithm incorporates the clinical presentation, signs, evolution, and differential diagnosis identified in this study and others.[2,8,15] Although the 'red flags/warning signs' included in the diagnostic algorithm are based on findings in Mexican patients, these

All within the same day the patient visit emergency room/doctor office

Figure 4. An algorithm for diagnosis and treatment of rhino-orbital-cerebral mucormycosis in patients with diabetes mellitus. Diabetes means any type of diabetes (1 or 2), controlled or noncontrolled, with or without DKA. Individuals with noncontrolled diabetes, hyperglycemia, and/or DKA have higher risk of infections and worse outcomes. Following discharge, we recommend a close follow-up of at least 72 h that includes a clinical and biochemical reevaluation, as well as a determination of the need, for additional surgery. For patients with diabetes mellitus who are receiving amphotericin B, particularly those with diabetic nephropathy, ambulatory monitoring of serum creatinine is important, as renal function may deteriorate over time. PAS: periodic acid Schiff, H&E: hematoxylin and eosin, GMS: Grocott-Gomori methenamine silver

findings have been also reported in the international literature.[36–38] Some of these clinical manifestations, such as the orbital apex syndrome, have been associated with worst prognosis and advanced infection.[38] The orbital apex syndrome caused by mucormycosis represents a surgical emergency that usually warrants orbital exenteration. As the orbital apex syndrome involves infarcted neurovascular tissue and threatens extension into the cavernous sinus, urgent surgical intervention is needed; medical therapy alone is seldom effective for this complication of orbital mucormycosis. Despite the advances in antifungal therapy with the advent of amphotericin B lipid formulations, isavuconazole, and posaconazole, the neurovascular infarction and threat to the cavernous sinus warrant urgent surgical resection.

Perioperative and intraoperative direct exam, KOH smear, and cytology performed during surgery may accelerate diagnosis and early treatment. Also, perioperative direct microscopic exam was suggested in the algorithm due to the favourable performance of KOH smear found in this study,

clinical experience in our institution, and prior reports in international literature.[13,15,39] We preferred KOH in our institution, because for stains such as calcofluor white stain, a fluorescence microscope is necessary and not always present in Mexican hospitals. Certainly, if a fluorescence microscope is available, then calcofluor white stain should be performed when feasible. Moreover, as has been recommended in a recent prospective study in India and by the British Society for Medical Mycology, further histopathological examinations with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), and Grocott-Gomori methenamine sliver (GMS) stains should be performed together with cultures of infected tissues.[13,31]

AmB formulations are considered the first line of treatment for mucormycosis. Lipid formulations of amphotericin B are associated with less renal dysfunction than that of AmBD and are effective as initial therapy for mucormycosis.[40] Although lipid formulations of AmB are not readily available in Mexico, they should be used where possible in

patients with diabetes mellitus, diabetic nephropathy, and concomitant nephrotoxic agents, where AmBD may induce renal failure.

Isavuconazole is another option for primary therapy of mucormycosis. Treatment with isavuconazole has shown similar outcomes to those of contemporaneously treated external control patients receiving amphotericin B when used as primary and salvage therapy.[6,41] Isavuconazole has been well tolerated, even for individuals with mild to moderate liver impairment.[42] For patients with underlying diabetic nephropathy, isavuconazole would be preferable to avoid further deterioration of renal function.

Following discharge, we recommend close follow-up within 72 h that includes a clinical and biochemical reevaluation, as well as a determination of the need for additional surgery. For patients with diabetes mellitus who are receiving amphotericin B, particularly those with diabetic nephropathy, ambulatory monitoring of serum creatinine is important, as renal function may deteriorate over time.

Ambulatory monitoring of sinus mucormycosis by endoscopy is a sensitive tool by which to assess antifungal response. Subtle changes in mucosal integrity and resolution of eschars can be accurately assessed by endoscopic evaluation. By comparison, assessment by CT scan of anatomic changes of sinus infiltrate caused by mucormycosis may lack the detection of finer detail afforded by nasal endoscopy.

Although exenteration is a standard of care for the orbital apex syndrome, more conservative surgical measures aimed at preserving the eye intact are pursued for management of mucormycosis of the orbit. Most cases of sino-orbital mucormycosis can be managed following the principles of antifungal therapy, reversal of immunosuppression, and surgical resection of infected tissue without loss of the eye. Sino-orbital mucormycosis can usually be managed without orbital exenteration providing that early diagnosis is established and that timely initiation of therapy is implemented. By comparison, a delay in exenteration for orbital apex syndrome may be complicated by intracranial extension and cavernous sinus thrombosis.

Reversal of immunosuppression or diabetic ketoacidosis is essential for a favorable outcome of sino-orbital mucormycosis. However, surgery and antifungal therapy are also important components of management, wherein each patient is managed individually by a multidisciplinary team.

This study has several limitations. As the data from cases and series reports is acquired retrospectively, information for individual patients was not always complete and could be heterogeneous. Since we could not exclude in this study a potential publication bias, even when the findings herein are consistent with previous reports, a prospective multicenter study should be performed to confirm these observations and conclusions. The data depend upon the publication of cases and therefore likely underestimate the true magnitude and scope of mucormycosis in Mexico. Nonetheless, this report represents the most comprehensive review of mucormycosis in Mexican patients and therefore advances our understanding in this population of more than 120 million people.[43] While the diagnostic algorithm proposed was built based upon clinical experience in a major medical center of Mexico and upon observations reported in the literature reviewed in this study, its use should be prospectively validated.

In summary, ROC mucormycosis in the population with diabetes mellitus is still the most frequently reported clinical presentation of this infection in Mexico. Combined management with antifungal therapy and surgery improves the outcome in mucormycosis when compared with antifungal therapy alone and is cornerstone in management of ROC mucormycosis. Early clinical diagnosis, specialized training in laboratory diagnostic mycology, multidisciplinary management, and timely antifungal therapy are important for successful management of mucormycosis.

References

1. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. *Clin Microbiol Infect*. 2011;17: 1859–1867.
2. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis*. 2005; 41: 634–653.

3. Lanternier F, Dannaoui E, Morizot G et al. A global analysis of mucormycosis in France: The RetroZygo study (2005–2007). *Clin Infect Dis*. 2012; 54 (Suppl. 1): 35–43.

4. Millon L, Herbrecht R, Grenouillet F et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). *Clin Microbiol Infect*. 2016; 22: 810.e1–810.e8.

5. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. *Clin Infect Dis*. 2008; 46: 1813–1821.

6. Marty FM, Ostrosky-Zeichner L, Cornely OA et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infect Dis*. 2016; 16: 828–837.

7. Walsh TJ, Skiada A, Cornely OA et al. Development of new strategies for early diagnosis of mucormycosis from bench to bedside. *Mycoses*. 2014; 57: 2–7.

8. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. *Blood*. 2011;118: 1216–1224.

9. Bitar D, Lortholary O, Le Strat Y et al. Population-based analysis of invasive fungal infections. *Emerg Infect Dis*. 2014; 20: 1149–1155.

10. Gamaletsou MN, Drogari-Apiranthitou M, Denning DW et al. An estimate of the burden of serious fungal diseases in Greece. *Eur J Clin Microbiol Infect Dis*. 2016; 35: 1115–1120.

11. Lelievre L, Garcia-Hermoso D, Abdoul H et al. Posttraumatic mucormycosis. *Medicine (Baltimore)*. 2014; 93: 373–382.

12. Vaezi A, Moazeni M, Rahimi MT et al. Mucormycosis in Iran: a systematic review. *Mycoses*. 2016: 59: 402–415.

13. Bala K, Chander J, Handa U et al. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. *Med Mycol*. 2015; 53: 248–257.

14. Gopalakrishnan R. Mucormycosis in patients without cancer: a case series from a tertiary care hospital in South India. *J Assoc Physicians India*. 2013; 61: 305–308.

15. Cornely OA, Arikan-Akdagli S, Dannaoui E et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. *Clin Microbiol Infect*. 2014; 20 (S3): 5–26.

16. Kyvernitakis A, Torres HA, Jiang Y et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. *Clin Microbiol Infect*. 2016; 22: 811.e1–811.e8.

17. Spellberg B, Kontoyiannis DP, Fredricks D et al. Risk factors for mortality in patients with mucormycosis. *Med Mycol*. 2012; 50: 611–618.

18. Kasapoglu F, Coskun H, Ozmen OA et al. Acute invasive fungal rhinosinusitis: Evaluation of 26 patients treated with endonasal or open surgical procedures. *Otolaryngol - Head Neck Surg*. 2010; 143: 614–620.

19. Sims CR, Ostrosky-Zeichner L. Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. *Arch Med Res*. 2007; 38: 90–93.

20. Di Carlo P, Pirrello R, Guadagnino G et al. Multimodal surgical and medical treatment for extensive rhinocerebral mucormycosis in an elderly diabetic patient: a case report and literature review. *Case Rep Med*. 2014; 2014:527062.

21. Bonifaz A, Tirado-Sanchez A, Calderon L et al. Mucormycosis in children: a study of 22 cases in a Mexican hospital. *Mycoses*. 2014; 57 (s3): 79–84.

22. Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R et al. Clinical features and outcome of mucormycosis. *Interdiscip Perspect Infect Dis*. 2014; 2014: 1–5.

23. Ameen M, Arenas R, Martinez-luna E et al. The emergence of mucormycosis as an important opportunistic fungal infection: five cases presenting to a tertiary referral center for mycology. *Int J Dermatol*. 2007; 46: 380–384.

24. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. *J Clin Invest*. 1984; 74: 150–160.

25. Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. *Curr Opin Infect Dis*. 2013; 26: 508–515.

26. Shirazi F, Farmakiotis D, Yan Y et al. Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. *PLoS One*. 2014; 9: 1–9.

27. Chan JCN, Gagliardino JJ, Baik SH et al. Multifaceted determinants for achieving. *Diabetes Care*. 2009; 32: 227–233.

28. Linetzky B, Curtis B, Frechtel G et al. Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIc study baseline data. *Diabetol Metab Syndr*. 2016; 8: 41.

29. Brath H, Paldánius PM, Bader G et al. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy. *Nutr Diabetes*. 2016; 6: e217.

30. Plowes Hernandez O, Prado Calleros HM, Soberon Marmissolle Daguerre GS et al. Rhino-orbito-cerebral mucormycosis. Management strategies to avoid or limit intracraneal affection and improve survival. *Acta Otorrinolaringol Esp*. 2015; 66: 348–352.

31. Schelenz S, Barnes RA, Barton RC et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. *Lancet Infect Dis*. 2015; 15: 461–474.

32. Encuesta Nacional de Salud, Internet. 2016. Available from: http://ensanut.insp.mx.

33. Alastruey-Izquierdo A, Mellado E, Pelaeez T et al. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP study). *Antimicrob Agents Chemother*. 2013; 57: 3380–3387.

34. Vitale RG, De Hoog GS, Schwarz P et al. Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales. *J Clin Microbiol*. 2012; 50: 66–75.

35. Chowdhary A, Kathuria S, Singh PK et al. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India. *Mycoses*. 2014; 57 (s3): 97–107.

36. Koc Z, Koc F, Yerdelen D et al. Rhino-orbital-cerebral mucormycosis with different cerebral involvements: infarct, hemorrhage, and ophthalmoplegia. *Int J Neurosci*. 2007; 117: 1677–1690.

37. Jiang N, Zhao G, Yang S et al. A retrospective analysis of eleven cases of invasive rhino-orbito-cerebral mucormycosis presented with orbital apex syndrome initially. *BMC Ophthalmol*. 2016; 16: 10.

38. Gamaletsou MN, Sipsas NV, Roilides E et al. Rhino-orbital-cerebral mucormycosis. *Curr Infect Dis Rep*. 2012; 14: 423–434.

39. McDermott NE, Barrett J, Hipp J et al. Successful treatment of periodontal mucormycosis: report of a case and literature review. *Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology*. 2010; 109: e64–e69.

40. Shoham S, Magill SS, Merz WG et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. *Med Mycol*. 2010; 48: 511–517.

41. Graves B, Morrissey CO, Wei A et al. Isavuconazole as salvage therapy for mucormycosis. *Med Mycol Case Rep*. 2016; 11: 36–39.

42. Desai A, Schmitt-Hoffmann A-H, Mujais S et al. Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment. *Antimicrob Agents Chemother*. 2016; 60: 3025–3031.

43. Instituto Nacional de Estadistica y Geografia (INEGI), Internet. 2016. Available from: http://www.inegi.org.mx

44. Gutiérrez-Delgado EM, Treviño-González JL, Montemayor-Alatorre A et al. Chronic rhino-orbito-cerebral mucormycosis: a case report and review of the literature. *Ann Med Surg*. 2016; 6: 87–91.

45. Alvarado-Lezama J, Espinosa-González O, García-Cano E et al. Gastritis enfisematosa secundaria a mucormicosis gástrica. *Cir Cir*. 2015; 83: 56–60.

46. Méndez HH, Hidalgo AR. Endodontic patient with rhinocerebral mucormycosis: clinical case report. Paciente endodóntico con mucormicosis rinocerebral: reporte de un caso. *Rev Odontológica Mex*. 2015; 19: 121–126.

47. Rodríguez-Gutiérrez G, Carrillo-Casas EM, Arenas R et al. Mucormycosis in a non-hodgkin lymphoma patient caused by *Syncephalastrum racemosum*: case report and review of literature. *Mycopathologia*. 2015; 180: 89–93.

48. Bonifaz A, Stchigel AM, Guarro J et al. Primary cutaneous mucormycosis produced by the new species *Apophysomyces mexicanus*. *J Clin Microbiol*. 2014; 52: 4428–4431.

49. Valdez-Geraldo CM, Zavala-Ruiz MG, Collado-Castro I et al. Mucormicosis rinocerebral: reporte de caso en escolar con cetoacidosis diabética. *Rev Mex Neurocienc*. 2014; 15: 229–233.

50. la Cruz D, Díaz-Salazar MX, Aguilera-Partida JA et al. Mucormycosis in a medullar aplasia patient: case report. *Rev Mex Oftalmol*. 2013; 87: 165–170.

51. Ramírez-dovala S, Sierra-téllez D, Contreras-rodríguez D et al. Caso clínico mucormicosis rino-órbito-cerebral causada por *Rhizomucor pusillus* en paciente diabético descompensado. *Dermatol rev Mex*. 2012; 56: 132–136.

52. González-ramos LA, Martínez-carballo EM, Rascón-alcantar A. Endocarditis por mucormicosis. *Bol Clin Hosp Edo Son*. 2012; 29: 77–80.

53. Telich-Tarriba JE, Perez-Ortiz AC, Telich-Vidal J. Necrotizing fasciitis caused by cutaneous mucormycosis: a case report. *Cir Cir*. 2012; 80: 462–465.

54. García-Romero MT, García-Méndez J, Arenas R et al. Zygomycosis in two hematologic cases. *Case Rep Infect Dis*. 2011; 2011: 181782.

55. Jacobo AGJ, Santiago PM, Elena GLC et al. Cutaneous zygomycosis in immunocompetent patients in Mexico. *Mycoses*. 2010; 53: 538–540.

56. Arce-Salinas CA, Perez-Silva E. Mucormycosis complications in systemic lupus erythematosus. *Lupus*. 2010; 19: 985–988.

57. Trejo S, Contreras R. Mucormicosis en un paciente con agranulocitosis secundaria a metimazol. Informe de un caso. *Gac Med Mex*. 2009; 145: 235–238.

58. Salinas-Lara C, Rembao-Bojórquez D, de la Cruz E et al. Pituitary apoplexy due to mucormycosis infection in a patient with an ACTH producing pulmonary tumor. *J Clin Neurosci*. 2008; 15: 67–70.

59. Bonifaz A, Macias B, Paredes-Farrera F et al. Palatal zygomycosis: experience of 21 cases. *Oral Dis*. 2008; 14: 569–574.

60. Robledo-ogazón F, Lizaola-pérez B, Mier-giraud F et al. Mucormicosis de la pared abdominal. Informe de un caso. *Cir Ciruj*. 2007; 75: 465–469.

61. Torres-Chavez T, Araiza Santibañez J, Sánchez P et al. Mucormicosis por *Rhizopus azygosporus* en paciente con diabetes mellitus tipo 2 y bocio or. *Rev Endocrinol y Nutr*. 2007; 15: 109–114.

62. Papadakis-Solis M, Larrea y Richerand E, Carrasco-Rueda CA et al. Mucormicosis rinoorbitaria y centellografia ósea de tres fases. Descripción de un caso. *Rev Inst Nal Enf Resp Mex*. 2007; 20: 210–212.

63. Carrillo-esper R, Elizondo-argueta S, Vicuña-gonzález M. Mucormicosis renal aislada. *Gac Med Mex*. 2006; 142: 511–514.

64. De I, Bernardino GH, Jarquín PZ et al. Mucormicosis rinocerebral. *Informe de un caso atípico*. *Dermatologia C*. 2005; 3 :272–275.

65. Manuel MH, Esther MD. Síndrome de ápex orbitario causado por mucormicosis orbitocerebral crónica e indolente: reporte de dos casos. *AN ORL MEX*. 2005; 50: 64–68.

66. Bravo TC. Mucormicosis Rinoorbital En Un Paciente Con Síndrome De Inmunodeficiencia Adquirida (SIDA) Y. *Rev Mex Oftalmol*. 2004; 78: 193–195.

67. Adrián L, García C. Experiencia de mucormicosis en el Hospital Juárez de México. *Rev Hosp Jua Mex*. 2004; 71: 3–13.

68. HR L-T. Un caso de gastroenterocolitis necrosante por zigomicosis. *Rev Mex Pediatr*. 2004; 71: 283–285.

69. Fujarte-Victorio AS, Casillas-Suarez C, Flores-Colin I et al. Mucormicosis pulmonar en un caso de carcinoma broncogénico de células pequeñas con diabetes mellitus tipo 2. *Rev Inst NAl Enf Resp Mex*. 2003; 16: 169–172.

70. Hernandez-Magaña R, Gomez-Barreto D, Puente A et al. mucormicosis rinoorbitaria nosocomial causada *Rhizopus oryzae* en un lactante desnutrido. *Bol Med Hosp Infant Mex*. 2001; 58: 35–47.

71. Barrón-soto AMA, Campos-navarro DLA, Antonio M et al. Morbilidad y mortalidad del paciente con mucormicosis rinorbitaria posterior al tratamiento médico quirúrgico oportuno. 2001; 11: 8–11.

72. Romero-zamora JL, Bonifaz A, Sánchez CJ et al. Mucormicosis rinocerebral. Reporte de doce casos. *Rev Medica del Hosp Gen México*. 2000; 63: 178–184.

73. Flores MS, Eugenia M, Manríquez V et al. Mucormicosis pulmonar diseminada. Informe de dos casos. *Rev Inst Nal Enf Resp Mex*. 2000; 13: 227–232.

74. Bross-Soriano D, Prado Calleros HM, Arrieta-Gomez J et al. Mucormicosis de la nariz y los senos paranasales.pdf. *An Medicos Hosp ABC*. 1998; 43: 95–100.

75. Rangel-Guerra RA, Martínez HR, Senz C et al. Rhinocerebral and systemic mucormycosis: clinical experience with 36 cases. *J Neurol Sci*. 1996; 143: 19–30.

76. Escobar A, Del Brutto OH. Multiple brain abscesses from isolated cerebral mucormycosis. *J Neurol Neurosurg Psychiatry*. 1990; 53: 431–433.

77. Pedroza-Terán LG. Mortalidad en pacientes con mucormicosis invasiva en el Hospital de Especialidades, *Centro Médico Nacional Siglo XXI*, reporte de casos. UNAM 2016.

78. Alamilla-Azpeitia RS. Aplicado a paciente con "mucormicosis cutánea" basado en el modelo de Dorothea Orem en el Hospital General de México Dr. Eduardo Liceaga. UNAM 2015.

79. Tepox-Padron A. Características clínicas y desenlace clínico de la mucormicosis en un hospital de tercer nivel de la ciudad de México. UNAM 2014.

80. Rodriguez-Gutiérrez G. Diagnóstico molecular de mucormicosis e identificación de los distintos agentes causales. UNAM 2013.

81. Avila-Cardoso C. Prevalencia y datos epidemiológicos de la mucormicosis en el servicio de otorrinolaringología adultos. UNAM 2010.

82. Gomez-Castelan A. Rehabilitacion de un paciente excenterado por mucormicosis con protesis orbitaria implantosoportada: reporte de caso clinico. UNAM 2007.

83. García Luis D. Diagnostico de mucormicosis, sus manifestaciones bucales y tratamiento; reporte de un caso clinico. *UNAM* 2005.

84. Rodriguez-Osorio C. Mucormicosis. Experiencia en el Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán." UNAM 2004.

85. Hilda AA. Diabetes, mucormicosis y sus manifestaciones bucales. *UNAM* 2002.

86. Luna-Olguin O. Presentacion de dos casos clinicos de mucormicosis del servicio de micologia del Hospital General de Mexico y revision de la literatura de 1980 a 1998. UNAM 2000.

87. Melendez-Rivera L. Mucormicosis, revision de la literatura y sobrevida del paciente en el Hospital de Especialidades del Centro Medico Nacional Siglo XXI, I.M.S.S. UNAM 1999.

88. Martinez-Martinez M. Mucormicosis en la unidad de cuidados intensivos, reporte de un caso y revision de la literatura. UNAM 1996.